Literature DB >> 21945182

Validation of a predictive survival model in Italian patients with cystic fibrosis.

Roberto Buzzetti1, Gianfranco Alicandro, Laura Minicucci, Sara Notarnicola, Maria Lucia Furnari, Gabriella Giordano, Vincenzina Lucidi, Enza Montemitro, Valeria Raia, Giuseppe Magazzù, Giuseppe Vieni, Serena Quattrucci, Alessandro Ferrazza, Rolando Gagliardini, Natalia Cirilli, Donatello Salvatore, Carla Colombo.   

Abstract

BACKGROUND: In 2001 Liou published a 5-year survival model using CFF Registry data. AIMS: To evaluate its validity in predicting survival in Italian CF patients.
METHODS: In a retrospective study on 945 patients, the 9 variables selected by Liou were analyzed, vital status on December 2008 recorded and observed and expected deaths compared. To develop a new model, patients were randomly divided into a derivation (n=475) and a validation sample (n=470).
RESULTS: A significant difference was found between observed and expected deaths based on Liou's model (62 vs 94), with a 34% reduction in mortality (p<0.05). A new model (based on FEV1, Staphylococcus aureus and Burkholderia cepacia complex infection, number of pulmonary exacerbations/year) was generated, that correctly predicted survival in the validation sample (31 observed vs 29 expected deaths, p=0.660).
CONCLUSIONS: The Liou model did not adequately predict 5-year survival in our CF population that, compared to the one in which it was originally tested, could benefit from 10 years of improvement in treatments and practice patterns. A new generated model, based on only four variables, was more accurate in predicting 5-year survival in Italian CF patients.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21945182     DOI: 10.1016/j.jcf.2011.08.007

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

Review 1.  Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls.

Authors:  Kathleen J Ramos; Ranjani Somayaji; David P Nichols; Christopher H Goss
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

2.  Palliative care for patients with cystic fibrosis #265.

Authors:  Juvianee Estrada-Veras; Hunter Groninger
Journal:  J Palliat Med       Date:  2013-02-26       Impact factor: 2.947

Review 3.  Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.

Authors:  Rhonda Szczesniak; Sonya L Heltshe; Sanja Stanojevic; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2017-01-20       Impact factor: 5.482

4.  Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients.

Authors:  Maria Talamo Guevara; Susanna A McColley; Karen Rychlik; Adrienne P Savant
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-06       Impact factor: 0.885

5.  A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning-Based Risk Prediction Models.

Authors:  Patricia J Rodriguez; David L Veenstra; Patrick J Heagerty; Christopher H Goss; Kathleen J Ramos; Aasthaa Bansal
Journal:  Value Health       Date:  2021-12-22       Impact factor: 5.101

6.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

7.  Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men.

Authors:  Shelby Sutton; Daniel Rosenbluth; Deepa Raghavan; Jie Zheng; Raksha Jain
Journal:  Pediatr Pulmonol       Date:  2013-03-04

8.  Prognostication and Risk Factors for Cystic Fibrosis via Automated Machine Learning.

Authors:  Ahmed M Alaa; Mihaela van der Schaar
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

9.  Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.

Authors:  Jaime L Rubin; Lasair O'Callaghan; Christopher Pelligra; Michael W Konstan; Alexandra Ward; Jack K Ishak; Conor Chandler; Theodore G Liou
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

10.  Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; Natalia Argel; Fadi Asfour; Perry S Brown; Barbara A Chatfield; Cori L Daines; Dixie Durham; Jessica A Francis; Barbara Glover; Theresa Heynekamp; John R Hoidal; Judy L Jensen; Ruth Keogh; Carol M Kopecky; Noah Lechtzin; Yanping Li; Jerimiah Lysinger; Osmara Molina; Craig Nakamura; Kristyn A Packer; Katie R Poch; Alexandra L Quittner; Peggy Radford; Abby J Redway; Scott D Sagel; Shawna Sprandel; Jennifer L Taylor-Cousar; Jane B Vroom; Ryan Yoshikawa; John P Clancy; J Stuart Elborn; Kenneth N Olivier; David R Cox
Journal:  BMC Med Res Methodol       Date:  2019-04-26       Impact factor: 4.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.